719
Views & Citations10
Likes & Shares
Obesity is a prevalence metabolic phenotype
caused by either abnormal metabolic homeostasis or gene-environmental
interactions. A small proportion of obesity persons are ineffective by
lifestyle modifications and controls. Personalized medicine for human obesity
will be utilized for obesity patients with pathological changes in the clinic.
This editorial documents some of this diagnostic topic and standard individual
treatments.
Keywords: Obesity, endocrinology, Human genome, Inflammatory factors, Neural disorder, Mental disorder, Obese treatment, Metabolic disruptions
BACKGROUND
Obesity is a prevalence metabolic and
physiological disorder caused by host-environmental consequences [1-6]. Most of
medications (food limitation or high-load of human exercise) are not always
work [7]. Formal medication should be emphasized in special cases of obesity
patients.
Pathologic factorials (endocrinological
factors)-leptin, thyroxine, insulin and many other hormonal dysfunctions:
Brain-visual-appetite axis (hypothalamic)
Psychiatric burden and disorder
Drug adverse effects (hormonal drugs,
antibiotics or other drugs associated with human liver dysfunction)
Inflammatory factors (TNF secretion)
Tumor-induced (pituitary tumors and others)
Physiological change (adipose cells or
tissues)
Genetic alleles and loci (loss-of-function or
copy number changes of key genes and molecules) [8-23].
MODERN DIAGNOSIS
To achieve targeted therapeutics for genetic/molecular abnormality, clinical treatments and new drug development may be important [24]. Combinations (drugs plus life-style) are widely recommended for obese patients, which are very useful for many other chronic diseases, such as HIV/AIDS and neoplasm metastasis [25-30]. Genetic/molecular abnormality needs to be evaluated by modern diagnosis [31-40].
PERSONALIZED
MEDICINE
In order to better manage human obese
patients, Personalized Medicine (PM) may be a future trend. Given the maturity
of PM in cancer treatment [41-44], these therapeutic strategies may be borrowed
to obese treatments. To achieve better obesity treatments, new drug development
and herbal medicine is also very useful in metabolic diseases [45-50]. Future
approaches may be urgent and necessary.
CONCLUSION
Human obesity is a strong risk factor for
human morbidity and mortality. PM in the clinic is indispensable part for
therapeutic promotions. After these genetic/molecular studies and personalized
medicine, all obese people can be controlled forever.
CONFLICT OF INTEREST
None
1.
World Health Organization (2018) WHO, obesity and
overweight. Available at: http//www.who.int/topics/obesity/en/
2.
Lu DY, Che JY, Wu HY, Yarla NS, Xu B, et al. (2018)
Obesity risks and managements Metabolomics 8: 155.
3.
Lu DY, Che JY, Lu Y, Wu HY, Yarla NS, et al. (2018) An
overview of obesity. Metabolomics 8: 200.
4.
Jainta N, Grzyb K, Otto-Buczkowska E (2019) Infection
diseases and vaccination in patients with diabetes. EC Diabetes Metab Res 3:
91-97.
5.
Lu DY, Che JY, Lu TR, Lu Y, Huang YK, et al. (2018)
Pathology and treatments of obesity. Trends Med 8: 157.
6.
Lu DY, Che JY, Putta S (2018) Obese study keep up the
momentum. Int J Endocrinol Res. 1: 4-8.
7.
Brestoff JJR, Artis D (2015) Immune regulation of
metabolic homeostasis in health and disease. Cell 161: 146-160.
8.
Yanai H (2017) VLDL is the leading actor in lipid
abnormality in patients with diabetes and obesity. J Endocrinol Metab 7:
101-102.
9.
Steculorum SM, Paeger L, Bremser S (2015) Hypothalamic
UDP increases in obesity and promotes feeding via P2Y6-dependent activation of
AgRP neurons. Cell 162: 1404-1417.
10.
Lee YS, Kim JW, Osborne O (2014) Increased adipocyte O2
consumption triggers HIF-1α, causing inflammation and insulin resistance in
obesity. Cell 157: 1339-1352.
11.
Quarta C, Schneider R, Tschop MH (2016) Epigenetic ON/OFF
switches for obesity. Cell 164: 341-342.
12.
Dalgaard K, Landgraf K, Heyne S, et al. (2016) Trim28
haplo-insufficiency triggers bi-stable epigenetic obesity. Cell 164: 353-364.
13.
Lu DY, Che JY, Lu Y, Huang YK, Lu TL, et al. (2019)
Mini-review of obesity, etiology progresses and different therapeutics. EC
Diabetes Metab Res 3: 98-102.
14.
Lu DY, Che JY, Yarla NS, Putta S, Lin LP, et al. (2019)
Human obesity, pathological and therapeutic advances. EC Pharmacol Toxicol 7:
231-238.
15.
Singh A, Srivastav R, Randey AK (2017) Protective role of
Terminalia chebula in streptozotocin-induced diabetic mice for wound healing
activity. Br J Med Med Res 22: 1-8.
16.
Smith RE, Tran K, Richards KM, Luo R (2015) Dietary
carbohydrates that modulate the immune system. Clin Immunol Endocrine Metab
Drugs 2: 35-42.
17.
Nzuza S, Zondi S, Hunchund R, Owira PMO (2017) Highly
active antiretroviral therapy associated metabolic syndrome and lipodystrophy:
Pathophysiology and current therapeutic interventions. J Endocrinol Metab 7:
103-116.
18.
Sgrawai P (2015) An overview on adverse drug reactions.
EC Pharm Sci 2: 181-182.
19.
Correa-Giannella ML, Machado UF (2013) SLC2A4 gene: A
promising target for pharmacogenomics of insulin resistance. Pharmacogenomics
14: 847-850.
20.
Brettdeld C, Maver A, Aumuller E, Peterlin B, Haslberger
AG (2017) Micro RNAs responsible for inflammation in obesity. J Endocrinol
Metab 7: 77-85.
21.
Van der Klaauw AA, Farooqi IS (2015) The hunger genes:
Pathways to obesity. Cell 161: 119-132.
22.
Schwartz S (2019) Psychiatry, psychology and climate
change. EC Psychol Psychiatry 8: 574-576.
23.
Putta S, Peluso I, Yarla NS (2017) Diabetes mellitus and
male aging, pharmacotherapeutics and clinical implications. Curr Pharm Design
23: 6321-6346.
24.
Lu DY, Che JY, Putta S, Shen Y, Xu B (2019) Human obesity
management, pathways and therapeutics beyond metabolic limitation. EC Diabetes
Metab Res 3: 4.
25.
Lu DY, Lu TR, Cao S (2013) Drug combinations in cancer
treatment. Clin Exp Pharmacol 3: 134.
26.
Lu DY, Wu HY, Yarla NS, Xu B, Ding J, et al. (2018) HAART
in HIV/AIDS treatments, future trends. Infect Disord Drug Targets 18: 15-22.
27.
Lu DY, Lu TR, Wu HY, Yarla NS, Ding J, et al. (2018)
HIV/AIDS curable study, new forms of therapeutic trinity. Rec Pat Antiinfect
Drug Discov 13: 217-227.
28.
Lu DY, Lu TR, Yarla NS, Wu HY, Xu B, et al. (2018) Drug
combination in clinical cancer treatment. Rev Recent Clin Trials 12: 202-211.
29.
Lu DY, Chen EH, Wu HY, Lu TR, Xu B, et al. (2017) Anti-cancer
drug combination, how far we can go through? Anticancer Agents Med Chem 17:
21-28.
30.
Lu DY, Chen EH, Lu TR, Ding J (2015) Anti-cancer drug
combinations, studies from different pathways. Cell Dev Biol 4: 166.
31.
Lu DY, Lu TR, Chen XL, Chen EH, Ding J, et al. (2015)
Cancer bioinformatics, its impacts on cancer therapy. Metabolomics 5: 133.
32.
Ocana A, Pandiella A (2010) Personalized therapies in the
cancer “omics” era. Mol Cancer 9: 202.
33.
Stransky B, Galante P (2010) Application of
bioinformatics in cancer research. An IMICS Perspective on Cancer Research, pp:
211-233.
34.
Putta S, Kilari EK (2015) A review on methods of
estimation of advanced glycation end products. World J Pharmac Res 4: 689-699.
35.
Lu DY, Qi RX, Lu TR, Wu HY (2017) Cancer bioinformatics
for update anti-cancer drug developments and personalized therapeutics. Rev
Recent Clin Trials 12: 101-110.
36.
Garg PK (2017) Potential of molecular imaging to advance
molecular medicine. Cancer Stud Mol Med Open 3: e3-e4.
37.
Lu DY, Che JY, Shen Y, Xu B (2019) Human obesity
therapeutics, modern diagnosis and biomarker. EC Pharmacol Toxicol 7: 997-1000.
38.
De Macedo JE (2015) Knowledge of the molecular signaling
pathways improves the chances of treatment of gastro-intestinal stromal tumors.
Can Stud Mol Med Open 2: 69-71.
39.
Meyer UA (2004) Pharmacogenetics five decades of
therapeutic lessons from genetic diversity. Nat Rev Genet 5: 669-676.
40.
Lu DY, Lu TR, Xu B, Ding J (2015) Pharmacogenetics of
cancer therapy: Breakthroughs from beyond? Future Sci OA 1: FSO.15-80.
41.
Lu DY, Chen XL, Ding J (2006) Individualized cancer
chemotherapy integrating drug sensitivity tests, pathological profile analysis
and computational coordination - An effective strategy to improve clinical
treatment. Med Hypotheses 66: 45-51.
42.
Lu DY (2014) Personalized cancer chemotherapy, an
effective way for enhancing outcomes in clinics.
43.
Lu DY, Lu TR, Che JY, Yarla NS (2018) Individualized
cancer therapy, what is the next generation? EC Cancer 2: 286-297.
44.
Lu DY, Lu TR, Che JY, Shen Y, Yarla NS (2018)
Individualized cancer therapy, future approaches. Curr Pharmacogenomics
Personalized Med 16: 156-163.
45.
Putta S, Yarla NS, Peluso I, Tiwari DK, Reddy GV, et al.
(2017) Anthocyanins: Possible role as multi-target therapeutic agents for
prevention and therapy of chronic diseases. Curr Pharm Design 23: 4475-4483.
46.
Lu DY, Che JY, Yarla NS, Zhu H, Lu TR, et al. (2018) Type
2 diabetes study, introduction and perspective. Open Diabetes J 8: 13-21.
47.
Lu DY, Che JY, Yarla NS, Wu HY, Lu TR, et al. (2018) Type
2 diabetes treatment and drug development study. Open Diabetes J 8: 22-33.
48.
Lu DY, Lu TR (2019) Drug discoveries from natural
resources. J Prim Health Care General Pract 3: 28.
49.
Lu DY, Lu TR (2019) Herbal medicine in new era. Hospice
Palliat Med Int J 3: 125-130.
50.
Lu DY, Lu TR, Chen EH, Yarla NS, Xu B, et al. (2018) Keep
up the pace of drug development evolution and expenditure. Cancer Rep Rev 2:
165.